Treatment Facility Volume Linked to Mortality in Multiple Myeloma

Share this content:
Patients with multiple myeloma who received care at higher-volume treatment facilities had a lower risk of death.
Patients with multiple myeloma who received care at higher-volume treatment facilities had a lower risk of death.

Patients with multiple myeloma who received care at higher-volume treatment facilities had a lower risk of death compared with those treated at lower-volume facilities, according to a study published in the Journal of Clinical Oncology.1

To evaluate the association between the number of patients with multiple myeloma treated annually at a treatment facility and all-cause mortality, researchers at the Mayo Clinic in Rochester, MN, analyzed data from 94,722 patients with multiple myeloma diagnosed between 2003 and 2011 who were treated at any 1 of 1333 facilities. Median age was 67 years and nearly 55% were men.

Facilities were classified by quartiles, with quartile 1 treating an average of fewer than 3.6 patients with multiple myeloma per year, quartile 2 treating between 3.6 and 6.1 per year, quartile 3 treating 6.1 to 10.3 per year, and quartile 4 treating more than an average of 10.3 patients annually. The median annual facility volume was 6.1 patients per year.

Results showed that 5.2% of patients were treated at facilities in quartile 1, 12.6% at quartile 2, 21.9% at quartile 3, and 60.3% at quartile 4. Median overall survival was 26.9 months, 29.1 months, 31.9 months, and 49.1 months at institutions classified as quartiles 1, 2, 3, and 4, respectively (P < .001).

After adjusting for confound factors, investigators found that facility volume was independently associated with all-cause mortality.

Specifically, patients treated at quartile 1 facilities had a 22% higher risk of death compared with those treated at quartile 4 facilities (hazard ratio [HR], 1.22; 95% CI, 1.17-1.28), and patients treated at quartile 2 facilities had a 17% higher risk vs those who received care at quartile 4 facilities (HR, 1.17; 95% CI, 1.12-1.21).

Patients treated at facilities classified in quartile 3 had a 12% increased risk of all-cause mortality compared with those in quartile 4 (HR, 1.12; 95% CI, 1.08-1.16).

RELATED: Overall Survival Statistics for the PANORAMA-1 Myeloma Trial Reported

This study is limited by potential selection bias as it does not take into account physician referral or patient self-selection, nor does it account for the annual physician volume or cumulative physician experience.

These findings build upon the mounting evidence that facility volume correlates with outcome in the management of hematologic malignancies.                        

Reference

  1. Go RS, Bartley AC, Crowson CS, et al. Association between treatment facility volume and mortality of patients with multiple myeloma. J Clin Oncol. 2016 Oct 23. doi: 10.1200/JCO.2016.68.3805 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters